Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR6 | P51684 | 2/20 | 0.48 |
| ▸ | CXCR2 | P25025 | 18/20 | 0.45 |
| ▸ | CXCR1 | P25024 | 13/20 | 0.45 |
| ▸ | CCR7 | P32248 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12576386 | 0.87 | CCR6 (0.46) | CCR6CXCR2CXCR1CCR7 | |
| SCHEMBL12576399 | 0.83 | CCR6 (0.48) | CCR6CXCR2CXCR1CCR7 | |
| SCHEMBL12576392 | 0.80 | CXCR2 (0.52) | CCR6CXCR2CXCR1CCR7 | |
| SCHEMBL12263779 | 0.78 | CCR6 (0.78) | CCR6CXCR2CXCR1CCR7 | |
| SCHEMBL12576690 | 0.73 | CCR6 (0.73) | CCR6CXCR2CXCR1CCR7 | |
| SCHEMBL13407350 | 0.73 | CCR6 (0.52) | CCR6CXCR2CXCR1CCR7 | |
| SCHEMBL12087132 | 0.72 | CCR6 (0.72) | CCR6CXCR2CXCR1CCR7 | |
| SCHEMBL14450061 | 0.72 | CXCR2 (0.48) | CCR6CXCR2CXCR1CCR7 | |
| SCHEMBL12310859 | 0.69 | CXCR2 (0.64) | CCR6CXCR2CXCR1CCR7 | |
| SCHEMBL12572429 | 0.69 | CXCR2 (0.64) | CXCR2CXCR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7964646-B2 | 3,4-DI-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands | SCHERING CORPORATION (US) | 2011-06-21 | — | — | US | disclosed |
| US-7964646-B2 | 3,4-DI-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands | SCHERING CORPORATION (US) | 2011-06-21 | — | — | US | disclosed |
| US-20070021494-A1 | 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands | SCHERING CORPORATION AND PHARMACOPEIA, INC. | 2007-01-25 | — | — | US | disclosed |
| US-20070021494-A1 | 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands | SCHERING CORPORATION AND PHARMACOPEIA, INC. | 2007-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021494-A1 | 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands | CCR1, ACKR3, CXCR1 | CCR6 19/4885CXCR2 7/4885CXCR1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.